| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3444 | Mnd Oxalate | Novel anticancer agent, inducing apoptosis, inhibiting migration and invasion |
|
| DCC3445 | Mnk1/2-in-9 | Novel highly potent and selective MNK1/2 kinases inhibitor |
|
| DCC3446 | Mnk2-in-8e | Potent and selective Mnk2 inhibitor |
|
| DCC3447 | Mntmpyp Pentachloride | Cell-permeable superoxide dismutase (SOD) mimetic |
|
| DCC3448 | Molibresib Besylate | Novel inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity |
|
| DCC3449 | Momelotinib Dihydrochloride Featured | Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis. |
|
| DCC3450 | Momordicoside L | Natural antioxidant and antidiabetic agent |
|
| DCC3451 | Mon-dnj | Novel iminosugar, downregulatiing the interferon γ receptor by dengue virus |
|
| DCC3452 | Moracin T | Natural potent antioxidant agent |
|
| DCC3453 | Morellic Acid | Natural analogue of (-)-gambogic acid acting as a potent inhibitor of global predominant MRSA USA300 |
|
| DCC3454 | Mosapramine Dihydrochloride | Potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors |
|
| DCC3455 | Naucledine | Natural antibacterial, antileishmanial, and antifungal agent |
|
| DCC3456 | Mp-10 Succinate | Potent and Specific PDE10A inhibitor |
|
| DCC3457 | Mp1104 | Novel mixed kappa-delta opioid receptor agonist with anti-cocaine properties and reduced side-effects in rats |
|
| DCC3458 | Mpges-1 Inhibitor-2 | Novel potent and selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor |
|
| DCC3459 | mpi621 | Novel anti-cancer agent, being more potent and safer than conventional indomethacin |
|
| DCC3460 | Mpk576 | Novel selective class IIb histone deacetylase inhibitor (HDACi), dose-dependently decreasing the viability of Acanthamoeba trophozoites |
|
| DCC3461 | Mpo-0029 | Potent and selective COX-2 inhibitor |
|
| DCC3462 | Mpp Dihydrochloride | Specific estrogen receptor α (ERα) antagonist |
|
| DCC3463 | Mpro-in-n3 | Novel main protease (Mpro) inhibitor, inhibiting MHV-A29, HCoV-229E, FOPV replication, and SARS-CoV-2 viral cell entry |
|
| DCC3464 | mps1 Inhibitor I | Novel Mps1 Kinase Inhibitor |
|
| DCC3465 | Mps-bay2b | Novel inhibitor of MPS1 |
|
| DCC3466 | Mpt0b206 | Novel tubulin polymerization inhibitor |
|
| DCC3467 | Mpt0b451 | Novel Dual HDAC6 and Tubulin Inhibitor, Displaying Anti-tumor Ability in Human Cancer Cells |
|
| DCC3468 | Mptp-in-22 | Novel mitochondrial permeability transition pore (mPTP) inhibitor |
|
| DCC3469 | Mpx-007 | Novel potent and selective antagonist of GluN2A-containing NMDA receptors |
|
| DCC3470 | Mq02-439 | Novel highly potent and selective 5-HT2C agonist |
|
| DCC3471 | Mr22388 | Novel, potent inducer of apoptosis via the MAP kinase pathways. Inhibitor of several kinases including the tyrosine kinase FLT3-ITD |
|
| DCC3472 | Mr6-31-2 | Novel inhibitor of the main protease (Mpro) of SARS-CoV-2 |
|
| DCC3473 | Mrgprx1 Pam 1t | Novel positive allosteric modulator (PAM) of mas-related G protein-coupled receptor X1 (MRGPRX1), reducing behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential in treating neuropathic pain |
|
